|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||147.00 - 150.82|
|52 Week Range||58.67 - 155.00|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||48.49|
|Earnings Date||Apr 28, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||144.70|
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating PRA Health Sciences, Inc. ("PRAH" or the "Company") (PRAH) relating to its proposed acquisition by ICON plc. Under the terms of the agreement, PRAH shareholders will receive 0.4125 shares of ICON stock and $80.00 in cash per share.
Rating Action: Moody's places PRA Holdings' ratings under review for upgrade on proposed acquisition by ICON PlcGlobal Credit Research - 26 Feb 2021New York, February 26, 2021 -- Moody's Investors Service ("Moody's") placed the ratings of PRA Holdings, Inc. and its subsidiaries (collectively "PRA") on review for upgrade following an announcement by ICON Plc (Baa3 RUR-down), that it has entered into a definitive agreement to acquire PRA. The ratings placed under review for upgrade include the Ba3 Corporate Family Rating, Ba3-PD Probability of Default Rating, and Ba3 senior secured credit facilities.
Rating Action: Moody's places ICON's rating under review for downgradeGlobal Credit Research - 26 Feb 2021Paris, February 26, 2021 -- Moody's Investors Service ("Moody's") has today placed ICON Plc's ("ICON" or "the company") Baa3 long-term issuer rating under review for downgrade. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.The ratings have been disclosed to the rated entity or its designated agent(s) and issued with no amendment resulting from that disclosure.These ratings are solicited.